Swiss Entertainment Stock News

SWX:SDZ
SWX:SDZPharmaceuticals

Assessing Sandoz Group (SWX:SDZ) Valuation After Strong One Year Shareholder Returns

Recent share performance snapshot Sandoz Group (SWX:SDZ) has seen a mix of short term pressure and longer term strength, with a 0.3% decline over the past day, 0.5% over the past week and 16.5% over the past month, but a 3.2% gain over the past 3 months and a 62.6% total return over the past year. See our latest analysis for Sandoz Group. The recent 30 day share price return of 16.5% contrasts with a 62.6% total shareholder return over the past year. This suggests that earlier gains have...
SWX:AMRZ
SWX:AMRZBasic Materials

Assessing Whether Amrize (SWX:AMRZ) Looks Undervalued After Its Recent Share Price Pullback

Why Amrize Stock Is On Investors’ Radar Amrize (SWX:AMRZ) has drawn fresh attention after a recent share price pullback, with the stock showing a 12.7% decline over the past month and a 1.1% slip over the past 3 months. See our latest analysis for Amrize. The recent 12.7% 1 month share price return decline comes after a relatively mild 2.7% negative share price return year to date. This suggests that momentum has cooled rather than strengthened in the short term. If this pullback has you...
SWX:ESUN
SWX:ESUNRenewable Energy

Edisun Power Europe (SWX:ESUN) Thin 2.2% Margin Tests Bullish Earnings Narratives

Edisun Power Europe (SWX:ESUN) has put out a mixed set of FY 2025 numbers, with first half revenue at CHF7.2 million and a basic EPS loss of CHF2.73, against a trailing twelve month picture that shows revenue of CHF50.9 million and basic EPS of CHF1.06. Over recent periods, revenue has moved between CHF7.8 million in 1H 2024 and CHF43.7 million in 2H 2024, while EPS has swung from a loss of CHF1.21 in 1H 2024 to EPS of CHF3.96 in 2H 2024, underlining just how volatile profitability has been...
SWX:GAM
SWX:GAMCapital Markets

GAM Holding (SWX:GAM) Losses Of CHF 40.7m Test Bullish Profitability Narratives

GAM Holding (SWX:GAM) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 25.7 million and basic EPS of CHF 0.038 loss per share, while trailing 12 month figures to the same point show revenue of CHF 62.5 million and a basic EPS loss of CHF 0.100897. Over the past three reported halves, revenue has moved from CHF 43.9 million in 1H 2024 to CHF 37.7 million in 2H 2024 and then to CHF 25.7 million in 1H 2025, alongside basic EPS losses of CHF 0.248253, CHF 0.08653 and...
SWX:NESN
SWX:NESNFood

Nestlé Waters Stake Sale Advances As Valuation Gap Draws Investor Attention

Nestlé is advancing the sale of its stake in its waters business, with private equity bidders moving forward in the process. The potential transaction is part of a broader effort to reshape the portfolio toward core areas such as coffee, pet food, nutrition, and food. The outcome of the bidding could influence how Nestlé allocates capital and manages its mix of brands in the coming years. For investors following SWX:NESN, this potential sale comes as the share price stands at CHF76.37, with...
SWX:VAHN
SWX:VAHNInsurance

Vaudoise Assurances Holding (SWX:VAHN) Combined Ratio Improvement Tests Bulls’ Profitability Narratives

Latest FY 2025 earnings snapshot Vaudoise Assurances Holding (SWX:VAHN) has just posted its FY 2025 numbers with first half revenue of CHF 777.1 million, basic EPS of CHF 28.89 and net income of CHF 84.1 million, alongside a combined ratio of 96.7%. Trailing 12 month figures show revenue of about CHF 1.5 billion, EPS of CHF 51.65 and net income of CHF 149.9 million. Over recent periods, revenue has moved from CHF 779.7 million in the first half of 2024 to CHF 777.1 million in the first half...
SWX:NOVN
SWX:NOVNPharmaceuticals

Cosentyx Pediatric HS Approval Adds New Angle To Novartis Valuation Story

Novartis (SWX:NOVN) received FDA approval for Cosentyx to treat moderate to severe hidradenitis suppurativa in pediatric patients aged 12 years and older. The decision makes Cosentyx the only approved IL-17A inhibitor for adolescent HS patients in the United States. The approval adds a new age group to Cosentyx's existing indications in immunology and dermatology. For investors tracking Novartis's immunology and dermatology efforts, this HS approval provides additional clarity on how the...
SWX:PGHN
SWX:PGHNCapital Markets

3 European Stocks Estimated To Be Up To 49.4% Below Intrinsic Value

Amidst heightened uncertainty and inflation risks, European markets have experienced notable declines, with the pan-European STOXX Europe 600 Index falling by 3.79% due to geopolitical tensions and rising energy costs. In this environment, identifying undervalued stocks becomes particularly appealing as investors seek opportunities that may offer a margin of safety against market volatility.
SWX:UBSG
SWX:UBSGCapital Markets

UBS Wealth Unit Favors Defensive Europe As Geopolitical Risks Shape Allocation

UBS Global Wealth Management has adjusted its global asset allocation to a more defensive stance in response to ongoing geopolitical tensions, including the Iran conflict. The firm has shifted its regional views, moving India and the euro zone to neutral while upgrading Switzerland and European healthcare. These changes affect how UBS positions client portfolios in energy sensitive and risk exposed markets. For investors tracking UBS Group (SWX:UBSG), the latest positioning changes at its...
SWX:MOVE
SWX:MOVEMedical Equipment

Assessing Medacta Group (SWX:MOVE) Valuation After Dividend Increase And Double Digit Growth Targets

Dividend and guidance draw attention to Medacta Group Medacta Group (SWX:MOVE) has attracted fresh investor interest after announcing an annual dividend of CHF 1.10 per share and issuing 2026 revenue growth guidance in a 10% to 14% range in constant currency. See our latest analysis for Medacta Group. The stock’s 1-day share price return of 1.62% contrasts with a weaker year-to-date share price return showing a 5.05% decline, while the 1-year total shareholder return of 14.85% points to...
SWX:LOGN
SWX:LOGNTech

Does Logitech’s New US$1.40 Billion Buyback and Racing Gear Launch Shift the Bull Case for (SWX:LOGN)?

In March 2026, Logitech International announced a new three-year share repurchase program of up to US$1.40 billion, alongside leadership changes and, on March 17, the global launch of the Logitech G RS H‑Shifter for sim racing enthusiasts. Together, the sizeable buyback authorization and expansion of Logitech’s high-end racing ecosystem highlight management’s focus on capital return and deepening engagement with committed gaming users. We’ll now examine how the US$1.40 billion share...
SWX:TXGN
SWX:TXGNMedia

Assessing TX Group (SWX:TXGN) Valuation After Profit Return And Lower Dividend

What the latest earnings and dividend move mean for TX Group TX Group (SWX:TXGN) has returned to profitability, reporting CHF 8.6 million in net income for 2025, and at the same time has set a lower annual dividend of CHF 4.00 per share. See our latest analysis for TX Group. Despite the move back into profit, the share price has been weak, with a 30 day share price return of an 11.27% decline and a year to date share price return of a 16.20% decline. However, the three year total shareholder...
SWX:EFGN
SWX:EFGNCapital Markets

EFG International Turns Volatility Into Structured Product Opportunity For Clients

EFG International (SWX:EFGN) CEO reports stronger client interest in structured products. The shift is linked to higher trading volatility tied to rising geopolitical tensions. Management commentary points to changing client priorities and product demand. EFG International, a Swiss private banking group, typically serves high net worth and ultra high net worth clients that focus on wealth preservation and tailored investment solutions. With geopolitical tensions feeding into more volatile...
SWX:STMN
SWX:STMNMedical Equipment

3 European Stocks That May Be Trading Below Their Intrinsic Value By Up To 32.5%

Amid heightened uncertainty and inflation risks, European markets have experienced a decline, with the STOXX Europe 600 Index falling by 3.79% due to geopolitical tensions and soaring energy costs. As investors navigate these turbulent times, identifying stocks that may be trading below their intrinsic value could offer potential opportunities for those looking to capitalize on market inefficiencies.
SWX:VAHN
SWX:VAHNInsurance

European Dividend Stocks To Consider Now

As European markets navigate heightened geopolitical tensions and soaring energy costs, investors are increasingly focused on the potential impact of these factors on inflation and economic stability. In this uncertain environment, dividend stocks may offer a measure of resilience by providing regular income streams that can help cushion against market volatility.
SWX:STMN
SWX:STMNMedical Equipment

European Growth Companies Backed By Insider Confidence

As European markets navigate the challenges of heightened energy prices and geopolitical tensions, investors are increasingly focused on companies that demonstrate resilience and potential for growth. In such uncertain times, stocks with high insider ownership can signal strong confidence from those who know the business best, making them attractive candidates for consideration in a volatile market environment.
SWX:BCGE
SWX:BCGEBanks

Assessing Banque Cantonale De Genève (SWX:BCGE) Valuation After Full Year 2025 Earnings Results

Earnings event puts Banque Cantonale de Genève in focus Banque Cantonale de Genève (SWX:BCGE) has drawn fresh attention after reporting full year 2025 results, with net interest income of CHF 347.8 million and net income of CHF 220.89 million. See our latest analysis for Banque Cantonale de Genève. The earnings release comes after a strong run in the share price, with a 90 day share price return of 34.17% and a year to date share price return of 30.89% at a latest share price of CHF32.2,...
SWX:NWRN
SWX:NWRNPharmaceuticals

Newron Pharmaceuticals (SWX:NWRN) Near Breakeven EPS Rekindles Debate On Rich P/S Multiple

Newron Pharmaceuticals (SWX:NWRN) has opened FY 2025 with first half revenue of €11.9 million and a basic EPS loss of €0.00, setting a cautious tone against a share price of CHF 14.64. Over recent periods, the company has seen revenue move from €3.4 million in H1 2024 to €48.0 million in H2 2024 and then to €11.9 million in H1 2025. Basic EPS has shifted from a loss of €0.51 in H1 2024 to a profit of €1.37 in H2 2024 and back to a marginal loss in the latest half, leaving investors focused on...
SWX:SKAN
SWX:SKANLife Sciences

SKAN Group (SWX:SKAN) Margin Slump To Loss In H1 2025 Tests Premium P/E Narrative

SKAN Group (SWX:SKAN) has just posted a softer first half for FY 2025, with revenue of CHF134.6 million and a basic EPS loss of CHF0.40, after generating CHF163.7 million in revenue and EPS of CHF0.61 in the first half of FY 2024. Over the last twelve months, revenue has run at CHF333.3 million with basic EPS of CHF0.72. This latest half-year print lands against a backdrop of shrinking trailing net margins, which keeps the focus squarely on how quickly profitability can stabilise. See our...
SWX:MCHN
SWX:MCHNMedia

MCH Group (SWX:MCHN) EPS Rebound To CHF 0.17 Tests Cautious Debt Narratives

MCH Group (SWX:MCHN) has opened FY 2025 with half year revenue of CHF 214.2 million and basic EPS of CHF 0.17, while trailing twelve month figures sit at CHF 401.6 million of revenue and basic EPS of CHF 0.15 as the company builds on its recent move into profitability. Over the past reported periods, revenue has moved from CHF 233.8 million in the first half of 2024 to CHF 187.4 million in the second half of 2024 and then to CHF 214.2 million in the first half of 2025. Over the same periods,...
SWX:IFCN
SWX:IFCNElectronic

INFICON Holding (SWX:IFCN) Margin Decline Challenges Bullish Growth Narratives In FY 2025 Results

INFICON Holding FY 2025 Earnings Snapshot INFICON Holding (SWX:IFCN) has posted its FY 2025 results with second half revenue of US$348.0 million and basic EPS of US$1.74, alongside net income of US$42.6 million, setting the tone for how the year closed out. The company has seen revenue move from US$349.8 million and basic EPS of US$2.48 in 2H 2024 to US$348.0 million and US$1.74 in 2H 2025, while trailing twelve month revenue sits at US$673.7 million with EPS of US$3.51, giving a clear read...